Chromocell Therapeutics Net Tangible Assets

Chromocell Therapeutics posts a net tangible assets of $-1.5M as of June 2026. That compares with $-6.5M in the prior-year period — up 76.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Chromocell Therapeutics's net tangible assets was $-6.5M. The latest reading is $-1.5M — a 76.9% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Net Tangible Assets is one piece of Chromocell Therapeutics's financial statement story. At $-1.5M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CHRO's net tangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Chromocell Therapeutics's other metric pages and overview cover the third.